Signals, Powered By EquityPandit
Camlin Fine Sciences has entered into joint venture (JV) with Singapore based, Pahang Pharma for research and development (R&D) purposes.
According to the JV contract, the company will receive royalty as certain percentage of net sales value. The proposed term of joint venture is 30 years, and the investment in the holding company will be in the proportion of 513 by the company and 493 by Pahang Pharma (S) Pte.
